PMID- 24725024
OWN - NLM
STAT- MEDLINE
DCOM- 20141128
LR  - 20220330
IS  - 1529-8027 (Electronic)
IS  - 1085-9489 (Linking)
VI  - 18
IP  - 4
DP  - 2013 Dec
TI  - A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy.
PG  - 321-30
LID - 10.1111/jns5.12046 [doi]
AB  - Intravenous immunoglobulin (IVIG) has become the standard treatment for 
      multifocal motor neuropathy (MMN) based on limited data. To critically assess the 
      efficacy, safety, and tolerability of 10% liquid IVIG (IVIG), 44 adults with MMN 
      were randomized 1 : 1 to either double-blind treatment of IVIG followed by 
      placebo for 12 weeks each or the reverse. Open-label IVIG was administered for 
      12 weeks at the beginning and end of the study for clinical stabilization, and 
      between double-blinded periods to prevent a carry-over effect. To avoid potential 
      worsening, switching to open-label IVIG was permitted if deterioration occurred 
      during blinded treatment. Mean maximal grip strength of the more affected hand 
      declined 31.38% during placebo and increased 3.75% during IVIG (p = 0.005). In 
      35.7% of participants, Guy's Neurological Disability scores for upper limbs 
      worsened during placebo and not during IVIG, whereas the converse was true in 
      11.9% (p = 0.021). Sixty-nine percent (69.0%) switched prematurely from placebo 
      to open-label IVIG and 2.4% switched from blinded to open-label IVIG (p < 0.001). 
      One serious adverse reaction (pulmonary embolism) and 100 non-serious reactions 
      (69 mild, 20 moderate, and 11 severe) to IVIG occurred. IVIG was effective in 
      improving disability and muscle strength, and was safe and well tolerated in 
      adults with MMN.
CI  - (c) 2013 Peripheral Nerve Society.
FAU - Hahn, Angelika F
AU  - Hahn AF
AD  - Department of Neurology, London Health Sciences Centre, London, Ontario, Canada.
FAU - Beydoun, Said R
AU  - Beydoun SR
FAU - Lawson, Victoria
AU  - Lawson V
CN  - IVIG in MMN Study Team
FAU - Oh, MyungShin
AU  - Oh M
FAU - Empson, Victoria G
AU  - Empson VG
FAU - Leibl, Heinz
AU  - Leibl H
FAU - Ngo, Leock Y
AU  - Ngo LY
FAU - Gelmont, David
AU  - Gelmont D
FAU - Koski, Carol L
AU  - Koski CL
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Peripher Nerv Syst
JT  - Journal of the peripheral nervous system : JPNS
JID - 9704532
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cross-Over Studies
MH  - Disability Evaluation
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Movement Disorders/complications/*drug therapy
MH  - Pain Measurement
MH  - Polyneuropathies/complications/*drug therapy
MH  - Severity of Illness Index
MH  - Treatment Outcome
OTO - NOTNLM
OT  - intravenous immunoglobulin
OT  - multifocal motor neuropathy
OT  - randomized placebo-controlled trial
FIR - Cupler, Edward J
IR  - Cupler EJ
FIR - Lopate, Glenn
IR  - Lopate G
FIR - Dimachkie, Mazen
IR  - Dimachkie M
FIR - Harati, Yadollah
IR  - Harati Y
FIR - Russell, James W
IR  - Russell JW
FIR - Zochodne, Douglas
IR  - Zochodne D
FIR - Chalk, Colin
IR  - Chalk C
FIR - Melanson, Michel
IR  - Melanson M
FIR - So, Yuen T
IR  - So YT
FIR - Gorson, Kenneth C
IR  - Gorson KC
FIR - Sharma, Khema
IR  - Sharma K
FIR - Melamed, Isaac
IR  - Melamed I
FIR - Weiss, Michael
IR  - Weiss M
FIR - Jakobsen, Johannes
IR  - Jakobsen J
EDAT- 2014/04/15 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/04/15 06:00
PHST- 2013/01/21 00:00 [received]
PHST- 2013/09/25 00:00 [revised]
PHST- 2013/10/18 00:00 [accepted]
PHST- 2014/04/15 06:00 [entrez]
PHST- 2014/04/15 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 10.1111/jns5.12046 [doi]
PST - ppublish
SO  - J Peripher Nerv Syst. 2013 Dec;18(4):321-30. doi: 10.1111/jns5.12046.